Estimating first-trimester combined screening performance for Down syndrome in dried blood spots versus fresh sera

Genetics in Medicine

Volumn 9, Issue 7, 2007, Pages 458-463

  Palomaki, Glenn E ^a,c   Neveux, Louis M ^a   Knight, George J ^a   Haddow, James E ^a   Lee, JoEllen ^b  

^a BROWN UNIVERSITY   (United States)

^b GENZYME GENETICS   (United States)

^c WOMEN AND INFANTS HOSPITAL   (United States)

Author keywords

Down syndrome; Dried blood spots; First trimester; Human chorionic gonadotropin; Pregnancy associated plasma protein A

Indexed keywords

CHORIONIC GONADOTROPIN; PROTEIN A;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DOWN SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LABORATORY DIAGNOSIS; PERFORMANCE; PRENATAL SCREENING; PROTEIN CONTENT;

ADULT; CHORIONIC GONADOTROPIN; COHORT STUDIES; DOWN SYNDROME; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; MASS SCREENING; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; SERUM;

EID: 34547650881     PISSN: 10983600     EISSN: None     Source Type: Journal    
DOI: 10.1097/GIM.0b013e31809861a9     Document Type: Article

References (23)

1. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, et al. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000;96:207-213.
2. Macri JN, Anderson RW, Krantz DA, Larsen JW, et al. Prenatal maternal dried blood screening with alpha-fetoprotein and free beta-human chorionic gonadotropin for open neural tube defect and Down syndrome. Am J Obstet Gynecol 1996;174:566-572.
3. Orlandi F, Damiani G, Hallahan TW, Krantz DA, et al. First-trimester screening for fetal aneuploidy: biochemistry and nuchal translucency. Ultrasound Obstet Gynecol 1997;10:381-386.
4. Verloes A, Schoos R, Herens C, Vintens A, et al. A prenatal trisomy 21 screening program using alpha-fetoprotein, human chorionic gonadotropin, and free estriol assays on maternal dried blood. Am J Obstet Gynecol 1995;172:167-174.
5. Spencer K, Macri JN, Carpenter P, Anderson R, et al. Stability of intact chorionic gonadotropin (hCG) in serum, liquid whole blood, and dried whole-blood filterpaper spots: impact on screening for Down syndrome by measurement of free beta-hCG subunit. Clin Chem 1993;39:1064-1068.
6. Hannon WH, Baily CM, Bartoshesky LE, Davin B, et al. Blood collection of filter paper for newborn screening programs, approved standards. National Committee for Clinical Laboratory Standards Document-LA4-A4. Fourth edition. Wayne, PA: National Committee for Clinical Laboratory Standards, 2003, 1-40.
7. Hoffman BR, Yu H, Diamandis EP. Assay of prostate-specific antigen from whole blood spotted on filter paper and application to prostate cancer screening. Clin Chem 1996;42:536-544.
8. National Committee for Clinical Laboratory Standards. Blood collection on filter paper for neonatal programs. 2nd edition: approved standard. Villanova, PA: National Committee for Clinical Laboratory Standards Publications LA4-A2, 1992.
9. Royston P, Thompson SG. Model-based screening by risk with application to Down's syndrome. Stat Med 1992;11:257-268.
10. Wald NJ, Rodeck C, Hackshaw AK, Walters J, et al. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). J Med Screen 2003;10:56-104.
11. Cuckle H. Improved parameters for risk estimation in Down's syndrome screening. Prenat Diagn 1995;15:1057-1065.
12. Centers for Disease Control. Vital and Health Statistics 2000-Natality Data Set, Series 21, No. 14 [Database on CD-ROM]. Hyattsville, MD: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics, 2002.
13. Hecht CA, Hook EB. Rates of Down syndrome at livebirth by one-year maternal age intervals in studies with apparent close to complete ascertainment in populations of European origin: a proposed revised rate schedule for use in genetic and prenatal screening. Am J Med Genet 1996;62:376-385.
14. Morris JK, Wald NJ, Watt HC. Fetal loss in Down syndrome pregnancies. Prenat Diagn 1999;19:142-145.
15. Canick JA, Lambert-Messerlian GM, Palomaki GE, Neveux LM, et al. Comparison of serum markers in first-trimester down syndrome screening. Obstet Gynecol 2006;108:1192-1199.
16. Neveux LM, Palomaki GE, Larrivee DA, Knight GJ, et al. Refinements in managing maternal weight adjustment for interpreting prenatal screening results. Prenat Diagn 1996;16:1115-1119.
17. Guthrie R, Susi A. A simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:338-343.
18. Wong PY, Mee AV, Doran TA. Studies of an alpha-fetoprotein assay using dry blood-spot samples to be used for the detection of fetal neural tube defects. Clin Biochem 1982;15:170-172.
19. Vieira Neto E, Carvalho EC, Fonseca A. Adaptation of alpha-fetoprotein and intact human chorionic gonadotropin fluoroimmunometric assays to dried blood spots. Clin Chim Acta 2005;360:151-159.
20. Mei JV, Alexander JR, Adam BW, Hannon WH. Use of filter paper for the collection and analysis of human whole blood specimens. J Nutr 2001;131:1631S-1636S.
21. Beaman JM, Akhtar N, Goldie DJ. Down's syndrome screening using free beta hCG: instability can significantly increase the Down's risk estimate. Ann Clin Biochem 1996;33(Pt 6):525-529.
22. Lambert-Messerlian GM, Eklund EE, Malone FD, Palomaki GE, et al. Stability of first- and second-trimester serum markers after storage and shipment. Prenat Diagn 2006;26:17-21.
23. Malone FD, Canick JA, Ball RH, Nyberg DA, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005;353:2001-2011.